COVID-19-mediated patient delay caused increased total ischaemic time in ST-segment elevation myocardial infarction.
COVID-19
Door-to-balloon time
Percutaneous coronary intervention
ST-segment myocardial infarction
Treatment delay
Journal
Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation
ISSN: 1568-5888
Titre abrégé: Neth Heart J
Pays: Netherlands
ID NLM: 101095458
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
accepted:
30
11
2021
pubmed:
20
1
2022
medline:
20
1
2022
entrez:
19
1
2022
Statut:
ppublish
Résumé
The current study aimed to evaluate changes in treatment delay and outcome for ST-segment elevation myocardial infarction (STEMI) in the Netherlands during the first coronavirus disease 2019 (COVID-19) outbreak, thereby comparing regions with a high and low COVID-19 hospitalisation rate. Clinical characteristics, STEMI timing variables, 30-day all-cause mortality and cardiovascular complications of all consecutive patients admitted for STEMI from 1 January to 30 June in 2020 and 2019 to six hospitals performing a high volume of percutaneous coronary interventions were collected retrospectively using data from the Netherlands Heart Registry, hospital records and ambulance report forms. Patient delay, pre-hospital delay and door-to-balloon time before and after the outbreak of COVID-19 were compared to the equivalent periods in 2019. A total of 2169 patients were included. During the outbreak median total treatment delay significantly increased (2 h 51 min vs 2 h 32 min; p = 0.043) due to an increased patient delay (1 h 20 min vs 1 h; p = 0.030) with more late presentations > 24 h (1.1% vs 0.3%) in 2020. This increase was particularly evident during the peak phase of COVID-19 in regions with a high COVID-19 hospitalisation rate. During the peak phase door-to-balloon time was shorter (38 min vs 43 min; p = 0.042) than in 2019. All-cause 30-day mortality was comparable in both time frames (7.8% vs 7.3%; p = 0.797). During the outbreak of COVID-19 patient delay caused an increase in total ischaemic time for STEMI, with a more pronounced delay in high-endemic regions, stressing the importance of good patient education during comparable crisis situations.
Sections du résumé
BACKGROUND
BACKGROUND
The current study aimed to evaluate changes in treatment delay and outcome for ST-segment elevation myocardial infarction (STEMI) in the Netherlands during the first coronavirus disease 2019 (COVID-19) outbreak, thereby comparing regions with a high and low COVID-19 hospitalisation rate.
METHODS
METHODS
Clinical characteristics, STEMI timing variables, 30-day all-cause mortality and cardiovascular complications of all consecutive patients admitted for STEMI from 1 January to 30 June in 2020 and 2019 to six hospitals performing a high volume of percutaneous coronary interventions were collected retrospectively using data from the Netherlands Heart Registry, hospital records and ambulance report forms. Patient delay, pre-hospital delay and door-to-balloon time before and after the outbreak of COVID-19 were compared to the equivalent periods in 2019.
RESULTS
RESULTS
A total of 2169 patients were included. During the outbreak median total treatment delay significantly increased (2 h 51 min vs 2 h 32 min; p = 0.043) due to an increased patient delay (1 h 20 min vs 1 h; p = 0.030) with more late presentations > 24 h (1.1% vs 0.3%) in 2020. This increase was particularly evident during the peak phase of COVID-19 in regions with a high COVID-19 hospitalisation rate. During the peak phase door-to-balloon time was shorter (38 min vs 43 min; p = 0.042) than in 2019. All-cause 30-day mortality was comparable in both time frames (7.8% vs 7.3%; p = 0.797).
CONCLUSIONS
CONCLUSIONS
During the outbreak of COVID-19 patient delay caused an increase in total ischaemic time for STEMI, with a more pronounced delay in high-endemic regions, stressing the importance of good patient education during comparable crisis situations.
Identifiants
pubmed: 35044627
doi: 10.1007/s12471-021-01653-9
pii: 10.1007/s12471-021-01653-9
pmc: PMC8767528
doi:
Types de publication
Journal Article
Langues
eng
Pagination
96-105Informations de copyright
© 2022. The Author(s).
Références
Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;39:119–77.
doi: 10.1093/eurheartj/ehx393
Scholz KH, Maier SKG, Maier LS, et al. Impact of treatment delay on mortality in ST-segment elevation myocardial infarction (STEMI) patients presenting with and without haemodynamic instability: results from the German prospective, multicentre FITT-STEMI trial. Eur Heart J. 2018;39:1065–74.
doi: 10.1093/eurheartj/ehy004
Wijns W, Naber CK. Reperfusion delay in patients with high-risk ST-segment elevation myocardial infarction: every minute counts, much more than suspected. Eur Heart J. 2018;39:1075–7.
doi: 10.1093/eurheartj/ehy069
Park J, Choi K, Lee JM, et al. Prognostic implications of door-to-balloon time and onset-to-door time on mortality in patients with ST-segment–elevation myocardial infarction treated with primary percutaneous coronary intervention. J Am Heart Assoc. 2019;8:e12188.
pubmed: 31041869
pmcid: 6512115
Cannon CP. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA. 2000;283:2941.
doi: 10.1001/jama.283.22.2941
Menees DS, Peterson ED, Wang Y, et al. Door-to-balloon time and mortality among patients undergoing primary PCI. N Engl J Med. 2013;369:901–9.
doi: 10.1056/NEJMoa1208200
Chieffo A, Stefanini GG, Price S, et al. EAPCI position statement on invasive management of acute coronary syndromes during the COVID-19 pandemic. Eur Heart J. 2020;41:1839–51.
doi: 10.1093/eurheartj/ehaa381
Mesnier J, Cottin Y, Coste P, et al. Hospital admissions for acute myocardial infarction before and after lockdown according to regional prevalence of COVID-19 and patient profile. Rochester, NY: Social Science Research Network; 2020.
Hammad TA, Parikh M, Tashtish N, et al. Impact of COVID-19 pandemic on ST-elevation myocardial infarction in a non-COVID-19 epicenter. Catheter Cardiovasc Interv. 2021;97:208–14.
doi: 10.1002/ccd.28997
Kwok CS, Gale CP, Kinnaird T, et al. Impact of COVID-19 on percutaneous coronary intervention for ST-elevation myocardial infarction. Heart. 2020;106:1805–11.
doi: 10.1136/heartjnl-2020-317650
C‑CF T, Cheung K‑S, Lam S, et al. Impact of coronavirus disease 2019 (COVID-19) outbreak on ST-segment–elevation myocardial infarction care in Hong Kong, China. Circ Cardiovasc Qual Outcomes. 2021;97:E194–7.
Claeys MJ, Argacha J‑F, Collart P, et al. Impact of COVID-19-related public containment measures on the ST elevation myocardial infarction epidemic in Belgium: a nationwide, serial, cross-sectional study. Acta Cardiol. 2021;76:863–9.
doi: 10.1080/00015385.2020.1796035
Clifford CR, Le May M, Chow A, et al. Delays in ST-elevation myocardial infarction care during the COVID-19 lockdown: an observational study. CJC Open. 2020;3:565–7.
doi: 10.1016/j.cjco.2020.12.009
Metzler B, Siostrzonek P, Binder RK, Bauer A, Reinstadler SJ. Decline of acute coronary syndrome admissions in Austria since the outbreak of COVID-19: the pandemic response causes cardiac collateral damage. Eur Heart J. 2020;41:1852–3.
doi: 10.1093/eurheartj/ehaa314
Gluckman TJ, Wilson MA, Chiu S‑T, et al. Case rates, treatment approaches, and outcomes in acute myocardial infarction during the coronavirus disease 2019 pandemic. JAMA Cardiol. 2020;5:1419.
doi: 10.1001/jamacardio.2020.3629
Xiang D, Xiang X, Zhang W, et al. Management and outcomes of patients with STEMI during the COVID-19 pandemic in China. J Am Coll Cardiol. 2020;76:1318–24.
doi: 10.1016/j.jacc.2020.06.039
De Rosa S, Spaccarotella C, Basso C, et al. Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. Eur Heart J. 2020;41:2083–8.
doi: 10.1093/eurheartj/ehaa409
RIVM. Regional differences in the coronavirus epidemic. 2020. https://www.rivm.nl/en/news/regional-differences-in-coronavirus-epidemic . Accessed 4 Jan 2021.
RIVM. Current information about COVID-19. 2021. https://www.rivm.nl/en/novel-coronavirus-covid-19/current-information . Accessed 8 Jan 2021.
RIVM. Ontwikkeling COVID-19 in grafieken. 2021. https://www.rivm.nl/coronavirus-covid-19/grafieken . Accessed 4 Jan 2021.
RIVM. Weekly coronavirus SARS-CoV‑2 figures. 2021. https://www.rivm.nl/en/coronavirus-covid-19/weekly-figures . Accessed 31 July 2021.
Chan DZL, Stewart RAH, Kerr AJ, et al. The impact of a national COVID-19 lockdown on acute coronary syndrome hospitalizations in New Zealand (ANZACS-QI 55). Lancet Reg Health West Pac. 2020;5:100056.
doi: 10.1016/j.lanwpc.2020.100056
Rattka M, Baumhardt M, Dreyhaupt J, et al. 31 days of COVID-19—cardiac events during restriction of public life—a comparative study. Clin Res Cardiol. 2020;109:1476–82.
doi: 10.1007/s00392-020-01681-2
Our World in Data. Coronavirus (COVID-19) hospitalizations—statistics and research. 2021. https://ourworldindata.org/covid-hospitalizations . Accessed 27 Apr 2021.
Derks L, Sturkenboom HN, Zaal M, et al. Association between public media and trends in new acute coronary syndrome presentations during the first COVID-19 wave in the Netherlands. Neth Heart J. 2021;29:577–83.
doi: 10.1007/s12471-021-01603-5